<DOC>
	<DOCNO>NCT02251236</DOCNO>
	<brief_summary>The project two track , one participant currently take elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate E/C/F/tenofovir alafenamide ( E/C/F/TDF E/C/F/TAF ) single-tablet regimen* ( STR ) ( Track A ) one participant begin therapy E/C/F/TDF E/C/F/TAF STR study ( Track B ) . Participants take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate ( E/C/F/TAF ) STR** ( available ) 24 week . *Co-formulation 150 mg elvitegravir , 150 mg cobicistat , 200 mg emtricitabine , 300 mg tenofovir disoproxil fumarate . **Co-formulation 150 mg elvitegravir , 150 mg cobicistat , 200 mg emtricitabine , 10 mg tenofovir alafenamide fumarate .</brief_summary>
	<brief_title>Elvitegravir ( EVG ) Cerebrospinal Fluid ( CSF ) Pharmacokinetics HIV-Infected Individuals</brief_title>
	<detailed_description>﻿﻿The propose project prospective , open-label treatment trial 14 HIV-infected adult . Participants enrol two track . Track A enroll participant take E/C/F/TDF E/C/F/TAF least 12 week . Track B enroll participant take ART prior exposure elvitegravir genotypic drug resistance component E/C/F/TDF E/C/F/TAF . CSF blood collect twice Track A ( two on-treatment assessment ) three time Track B ( one pre-treatment , two on-treatment assessment ) . If possible , plan time assessment bridge transition E/C/F/TDF E/C/F/TAF participant ideally one CSF collection regimen , enable pair comparison tenofovir concentration two tenofovir formulation . We estimate 28 on-treatment CSF collection sufficient provide small-sample estimate distribution elvitegravir , tenofovir TAF CSF .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Adult men woman age 1860 year . Able willing provide inform consent . Presence HIV1 infection document licensed ELISA test kit confirm Western blot HIV RNA . Track A ( Currently take E/C/F/TDF E/C/F/TAF ) : Taking E/C/F/TDF E/C/F/TAF least 3 month prior screen undetectable plasma HIV1 RNA ( ≤ 40 copies/mL ) Track B ( Currently take ART ) : Off ART least 3 month . Prior exposure TDF FTC allow subject must primary genotypic drug resistance mutation elvitegravir , tenofovir , emtricitabine ( see Exclusion Criteria ) Plasma HIV1 RNA ≥ 5,000c/mL CD4+ Tcell count ≥200cells/mm3 . Track B : Presence primary drug resistance mutation EVG , tenofovir , emtricitabine . Use drug abuse alcohol would interfere adherence completion study . While onstudy , subject instruct consume alcohol 48 hour prior pharmacokinetic sampling day . Pregnancy breastfeed . Women childbearing potential must negative serum urine pregnancy test within 14 day prior study entry day entry . Chronic , severe , medical condition , opinion investigator , would interfere subject ability participate protocol . Use prohibit protocolspecified drug , prescription overthecounter , within 14 day prior study entry . Bleeding abnormality contraindication lumbar puncture . Moderate severe cognitive impairment history base Montreal Cognitive Assessment . Hepatitis B surface antigen ( HBsAg ) positive ( Positive antiHBs antibody negative HBsAg result acceptable ) Hepatitis C antibody ( HCV Ab ) positive Laboratory parameter document within 21 day prior study entry would increase risk adverse event : 1 . Hemoglobin &lt; 12.5 g/dL men ; &lt; 11.5 g/dL woman ; 2 . Platelet count &lt; 100,000 platelets/mm3 ; 3 . AST ( SGOT ) ALT ( SGPT ) &gt; 1.5 x upper limit normal ( ULN ) ; 4 . Estimated GFR &lt; 70 ml/min 5 . Weight le 50 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Stribild</keyword>
	<keyword>Genvoya</keyword>
	<keyword>elvitegravir</keyword>
	<keyword>Cerebrospinal Fluid</keyword>
	<keyword>HIV</keyword>
</DOC>